The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis
Abstract
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major bleeding among patients with venous thromboembolism in relation to both malignancy and the achieved INR. PATIENTS AND METHODS: In a retrospective analysis, the INR-specific incidence of venous thromboembolic and major bleeding events during oral anticoagulant therapy was calculated separately for patients with and without malignancy. Eligible patients participated in two multicenter, randomized clinical trials on the initial treatment of venous thromboembolism. Patients were initially treated with heparin (standard or low-molecular weight). Treatment with vitamin K antagonists was started within 1 day and continued for 3 months, with a target INR of 2.0 to 3.0. RESULTS: In 1,303 eligible patients (264 with malignancy), 35 recurrences and 12 bleeds occurred. Patients with malignancy, compared with nonmalignant patients, had a clinically and statistically significantly increased overall incidence of recurrence (27.1 v 9.0, respectively, per 100 patient-years) as well as bleeding (13.3 v 2.1, respectively, per 100 patient-years). In both groups of patients, the incidence of recurrence was lower when the INR was above 2.0 compared with below 2.0. CONCLUSION: Although adequately dosed vitamin K antagonists are effective in patients with malignant disease, the incidence of thrombotic and bleeding complications remains higher than in patients without malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Self-citationA Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A. G., Demers, C., Kovacs, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,192
Self-citationKoopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,111
Self-citationLow-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Bleeding Complications in Oral Anticoagulant Therapy: An Analysis of Risk Factors
van der Meer, F. J. M. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410130073007 · Cited by 433
Hemorrhagic Complications of Anticoagulant Therapy
Coon, W. W. (1974) · Archives of Internal Medicine · doi:10.1001/archinte.133.3.386 · Cited by 316
Gitter, M. J., Jaeger, T. M., Petterson, T. M., Gersh, B. J., & Silverstein, M. D. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.8.725 · Cited by 276
Landefeld, C. S., Cook, E. F., Flatley, M., Weisberg, M., & Goldman, L. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90004-0 · Cited by 264
Assessment of a Bleeding Risk Index in Two Cohorts of Patients Treated with Oral Anticoagulants
van der Meer, F. J. M., Rosendaal, F. R., Vandenbroucke, J. P., & Briët, E. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650514 · Cited by 154
The Efficacy and Safety of Oral Anticoagulation in Patients with Cancer
Bona, R., Sivjee, K. Y., Hickey, A. D., Wallace, D. M., & Wajcs, S. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649881 · Cited by 109
Antithrombotic Strategies in Patients with Cancer
Prandoni, P. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657517 · Cited by 78
Westerveld, B. D., Pals, G., Lamers, C. B. H. W., Défize, J., Pronk, J. C., Frants, R. R., Ooms, E. C. M., Kreuning, J., Kostense, P. J., Eriksson, A. W., et al. (1987) · Cancer · doi:10.1002/1097-0142(19870301)59:5<983::aid-cncr2820590522>3.0.co;2-o · Cited by 77
Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin
Petitti, D. B., Strom, B. L., & Melmon, K. L. (1989) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(89)90073-5 · Cited by 77
Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism
Wester, J. P., de Valk, H. W., Nieuwenhuis, H. K., Brouwer, C. B., van der Graaf, Y., Meuwissen, O. J., Hart, H. C., Sixma, J. J., & Banga, J. D. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650643 · Cited by 53
Schulman, S., Stigendal, L., Jansson, J.-H., et al. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb19606.x · Cited by 10
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Metadata
- Authors
- Hutten, B. A., Prins, M. H., Gent, M., Ginsberg, J., Tijssen, J. G. P., & Büller, H. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-09-17
- Volume
- 18
- Issue
- 17
- Pages
- 3078-3083
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1955610473
- Cited by
- 748
- References
- 16
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.